ESBATech
Antibody framework therapeutics
Founded in 1998 as a spin out of the University of Zurich, ESBATech is committed to becoming one of the leading developers of fully human antibody fragments for therapeutic applications. The company applies its proprietary, fully human single-chain...Founded in 1998
Homepage: http://www.esbatech.com
Total money raised: $63M
Wagistr. 21
CH-8952 Zurich-Schlieren
CHE
CH-8952 Zurich-Schlieren
CHE
Phone: 41-44-733-4900
Updated on Apr 19, 2010
ESBATech at CrunchBase
Dominik Escher Chief Executive OfficerESBATech at CrunchBase
Martin Gertsch Chief Financial Officer
Past
September, 2009
ESBATech was acquired by Alcon
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG 
invest.alconinc.com
August, 2008
ESBATech raised $22M in a Series B round from SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Bioventures, BioMedinvest, and VI Partners
ESBATech rounds up $22M in second round 
fiercebiotech.com
August, 2006
ESBATech raised $41M in a Series B round from SV Life Sciences, Clarus Ventures, HBM BioVentures, HBM BioCapital, Novartis Venture Fund, BioMedinvest, and VI Partners
ESBATech Closes USD 41M Series B Venture Financing 
esbatech.com
1998
ESBATech was founded in 1998